What does a Fully Integrated Mechanical Thrombectomy System cost?

Capital equipment and consumable pricing for stroke, limb, and venous thrombectomy platforms—2026 edition

A fully integrated mechanical thrombectomy system sits at the intersection of high-acuity neurovascular care and high-cost capital procurement. Hospitals typically face two separate cost categories: the durable aspiration pump/control unit (one-time capital investment of $50,000–$150,000+ for leading platforms), plus consumable per-procedure costs of $1,300–$9,000 depending on device type, vessel access, and supplier negotiating power. The Penumbra Lightning 12 Indigo System costs $9,000, with aspiration catheters starting at a minimum of $1,300 , while Inari embolectomy catheters range from $1,700 to $8,500 depending on French size, with sheaths from $1,800 to $3,600 . Actual net prices vary dramatically by GPO affiliation, volume commitments, and capitation agreements. MedSource does not yet have aggregate quote data on system-level capital costs; pricing in this article is drawn from published spec sheets, medical materials distributor listings, and peer-reviewed cost analyses.

What the typical range is

Capital equipment (pump, controller, console, tubing): $50,000–$180,000 per system, with wide variance by manufacturer and feature set.

Consumables per procedure (catheters, dilators, separators, accessories): $1,300–$9,000 depending on:

• Vessel diameter and access site (neuro vs. peripheral vs. venous)
• Device generation (newer aspiration systems with integrated sensors cost more)
• Single-use vs. multi-use component bundles
• Capitation pricing vs. fee-for-service pricing

Mechanical thrombectomy devices held 36.2% market share in the overall thrombectomy space in 2025, with Stryker launching the ARTiX Thrombectomy System in March 2025, a dual-mode device combining aspiration and mechanical techniques . The market is consolidating: Boston Scientific announced a definitive agreement to acquire Penumbra for approximately $374 per share in January 2026 , concentrating advanced platforms among major OEMs.

What pushes price up — features, certifications, support tier

Computer-assisted intelligence & real-time feedback – The Penumbra System is engineered for quick and effective clot removal, with the Penumbra ENGINE generating nearly pure vacuum to power clot capture . Integrated vacuum algorithms, clot-detection sensors, and automated aspiration pressure modulation add $1,500–$3,000 to per-procedure cost compared to manual aspiration devices.

FDA indication breadth – A single platform cleared for neuro, peripheral arterial, venous, and pulmonary embolism indications commands higher pricing than single-indication devices. The FlowTriever system was the first mechanical thrombectomy system to receive FDA 510(k) clearance for the treatment of pulmonary embolism , opening a higher-reimbursement indication that justifies device investment.

Catheter technology (atraumatic tip design, hypotube construction, French size compatibility) – Newer-generation catheters with soft, angled tips and improved trackability through tortuous anatomy (especially in neuro cases) cost 20–40% more per unit than commodity designs.

On-site technical support and training – Vendors bundling hands-on neurointerventional training, case management, and 24/7 technical support add $15,000–$40,000 annually to total cost of ownership. The Penumbra System should only be used by physicians who have received appropriate training in interventional neuro-endovascular techniques ; compliance requires vendor-led certification.

Reusable vs. single-use—true cost transparency – Ensure contractual clarity on whether the pump, tubing harness, and dilators are reusable (reducing per-case consumable cost by 10–15%) or single-use.

What pushes price down — refurbished, older generation, lease, GPO contracts

Capitation/bundled pricing – Negotiated capitated pricing models yielded total cost savings associated with equipment compared to fee-for-service; overall mean capitation costs were lower than virtual cases, potentially serving as a model for other centers in controlling costs . Hospitals performing >75 cases/year should negotiate per-case packages ($2,500–$5,500 all-in) rather than itemized purchasing.

GPO affiliation (Vizient, Premier, MedAssets) – Group purchasing organizations secure 15–25% rebates off list pricing for Stryker, Medtronic, and Boston Scientific (post-Penumbra) platforms, particularly for multi-year commitments.

Prior-generation devices – The Penumbra System was approved in 2008, and stent retrievers in 2012 . Older Penumbra 5MAX catheters, first-generation Trevo retrievers, and early-model AngioJet systems (if still available through secondary vendors) can be sourced 30–50% below current pricing but may lack newer sensor technology or FDA clearances for expanded indications.

Leasing vs. capital purchase – For low-volume centers (<40 cases/year), operating leases ($8,000–$15,000/month) or usage-based equipment agreements avoid upfront $80,000–$150,000 capital outlays. Break-even analysis typically favors ownership by year 3–4 for tertiary stroke centers.

Refurbished/reconditioned pumps – Some vendors (especially Medtronic and Stryker) offer certified refurbished aspiration pumps at 40–50% discount, with full warranty. Acceptable for volume-limited programs; verify FDA recertification documentation.

Hidden costs — install, training, calibration, consumables, service contracts

Installation & site prep – Angiography suite integration, electrical upgrades, waste management setup: $5,000–$15,000 one-time.

Mandatory physician/staff training – Most vendors require on-site neurointerventional certification (2–5 physicians minimum) and nursing/technician competency testing before first case. Budget $8,000–$25,000 per site, often included in capital agreements but not always transparent.

Annual service contracts – Warranty extensions, preventive maintenance, emergency support: $4,000–$12,000/year for aspiration pump systems. Failure to maintain voids reliability guarantees.

Consumable inventory carrying costs – Mechanical thrombectomy devices have <24–36 month shelf lives. Devices are labeled with a 24 month shelf-life supported by accelerated and real-time shelf-life testing including packaging integrity and component functional performance testing . Over-ordering to avoid stockouts can lock up $20,000–$50,000 in inventory.

Procedural add-ons (guide catheters, microwires, balloons, contrast) – Per-case cost of supporting materials (access catheters, exchange wires, balloon guide catheters for stent retriever cases) can add another $800–$2,000 beyond the thrombectomy device itself.

Reimbursement delay risk – Medicare reimburses these procedures under MS-DRG 023-027 at USD 7,200–8,500 . Device costs often exceed reimbursement for complex, multi-device cases; systems-level contracts are essential to bridge the gap.

How to negotiate — concrete tactics

1. Benchmark against capitation baselines. Request actual contracts from comparable hospitals (via CMS cost reports or GPO reference). Most centers performing 50+ cases should target $3,500–$5,000 all-in per procedure for consumables under bundled agreements.

2. Lock in multi-year volume commitments. Offer to standardize on one platform (vs. dual-sourcing from Penumbra and Stryker) in exchange for 20–30% price reductions and volume-based rebates on future purchases.

3. Separate capital from consumables. Negotiate pump cost separately from per-case catheter/consumable pricing. Vendors often bundle to obscure real consumable costs. Request itemized breakdowns.

4. Leverage FDA indication expansion. If a newer device has broader indications (e.g., venous thromboembolism + acute limb ischemia), negotiate blended pricing across indications rather than higher fees for newer approvals.

5. Demand transparent tiering. Ensure contracts specify escalating rebates at 50, 75, and 100+ cases per year. A 50-case center should not pay the same per-unit price as a 200-case center.

6. Request service cost caps. Do not accept open-ended annual support contracts. Negotiate fixed service fees with itemized coverage; challenge non-critical add-ons like quarterly in-service training beyond initial certification.

7. Negotiate second-source terms. If you select Boston Scientific/Penumbra, negotiate contract language preserving right to trial competing platforms (Stryker, Medtronic) to prevent vendor lock-in over time.

When the price feels off — red flags

• Vendor quotes consumable cost alone without capital cost. Aspiration pumps don't appear free; clarify whether capitated pricing is all-inclusive or if equipment maintenance/replacement is billed separately.

• Large delta between "list price" and negotiated price. List prices (e.g., $9,000 for Penumbra Indigo) are often fiction; red flag if your hospital is asked to pay >70% of published list price without volume justification.

• Single-use catheters priced identically to prior-generation reusable models. Verify whether cost increase reflects true technology gain (e.g., sensor integration) or just margin expansion.

• Exclusive vendor agreements without price-per-case transparency. Some hospitals commit 100% of volume to one OEM without documented per-case costs. This invites price creep post-signature.

• Training costs not included in capital package. Demand full neurointerventional certification and competency testing as part of system acquisition, not as a separate $15,000+ line item.

• Shelf-life waste not addressed in inventory policy. If your organization orders $60,000/year in consumables but <60% are used (due to case volume swings), negotiate pay-for-use or consignment inventory models instead.

• Service contracts with undefined scope. "Comprehensive support" means nothing. Require itemized coverage: on-site emergency repair, parts replacement, remote troubleshooting, hours of availability, and response time guarantees.

---

Sources

JVS Vascular Insights (2024). Pricing data from Medical Materials, Inc distributor listings and vendor spec sheets for Inari FlowTriever and Penumbra Indigo.

Shah et al., Journal of Neurointerventional Surgery (2020). Capitated pricing models for stroke thrombectomies; Cooper Hospital / University of Pittsburgh analysis of cost-negotiated bundled equipment packages.

Coherent Market Insights & FinancialContent (2025–2026). Stryker ARTiX launch announcement; Boston Scientific acquisition of Penumbra for $374/share.

Mordor Intelligence (2026). Medicare reimbursement data; MS-DRG 023-027 at $7,200–$8,500; 2026 AHA/ASA guidelines on mechanical thrombectomy coverage.

FDA 510(k) Summary (Trevo XP ProVue), DEN150049. Shelf-life testing and component durability specifications for stent retriever devices.

Penumbra Inc. Product labeling (2025). System architecture: RED Reperfusion Catheters, Penumbra ENGINE Aspiration Source, accessories; FDA 510(k) clearance December 2007.

---

Note: Pricing in this article reflects publicly available distributor lists, published cost analyses, and vendor spec sheets as of May 2026. MedSource will update this estimate as aggregate quote data accrue from procurement partners. Actual net pricing varies significantly by facility size, case volume, and negotiating leverage. Always request itemized, all-inclusive per-case pricing and separate capital cost for pump systems before committing to platform selection.